CLAIMS

1. The compounds having the following the general formula:



(I)

where:

- R_1 is chosen from hydrogen, a lower alkyl, and a suitable protective group of the amine;
- R_2 is chosen between hydrogen, and a suitable protective group of the carboxyl;
- R_3 is chosen from a benzyl, substituted benzyl, allyl, hydroxypropyl, hydroxyethyl, and lower alkyl;
- n is a number chosen from 0, 1, 2;

including the salts, the racemates, the individual enantiomeric forms, the individual diastereoisomeric forms, or their mixtures.

2. The compounds according to Claim 1, characterized in that said lower alkyl is a C_1-C_4 alkyl group.

3. The compounds according to Claim 1, characterized in that said suitable protective group is chosen between an alkyl ester and a benzyl ester.

4. The compounds according to Claim 1, characterized in that n is chosen equal to 1, and R_3 is chosen as a benzyl.

5. The compounds according to Claim 1, characterized in that n is chosen equal to 1, and R_3 is chosen as an allyl.

6. The compounds according to Claim 1, characterized in that n is chosen equal to 2, and R_3 is chosen as a benzyl.

7. The compounds according to Claim 1, characterized in that n is chosen equal to 2, and R_3 is chosen as an allyl.

8. The compounds according to Claim 1, characterized in that n is chosen equal to 2, and R_3 is chosen as a methyl.

9. A process for the preparation of the compounds according to Claim 1,

which comprises the following steps:

- formation, in suitable reaction conditions, of a carbanion in position 3 starting from the compound (Ia) having the following formula:



(Ia)

or by one of its suitable derivatives,

- alkylation of said carbanion to obtain the compound of the general formula (I)

including the salts, the racemates, the individual enantiomeric forms, the individual diastereoisomeric forms, or their mixtures.

10. A process according to Claim 9, characterized in that:

- R_1 is chosen from hydrogen, a lower alkyl, and a suitable protective group of the amine;
- R_2 is chosen between hydrogen, and a suitable protective group of the carboxyl;
- R_3 is chosen from benzyl, substituted benzyl, allyl, hydroxypropyl, hydroxyethyl, lower alkyl;

n is a number chosen from 0, 1, 2;

11. The process according to Claim 10, characterized in that said lower alkyl is a C_1-C_4 alkyl group.

12. The process according to Claim 9, characterized in that said R_3 is chosen as an allyl.

13. The process according to Claim 12, characterized in that said allyl is converted into a hydroxyethyl or a hydroxypropyl.

14. Use of the compounds according to Claim 1 as intermediates in the synthesis of peptidomimetic compounds.

15. Use according to Claim 14 in the synthesis of peptidomimetic

compounds comprising the sequence RGD (Arg-Gly-Asp).

16. Peptidomimetic compounds comprising the sequence RGD (Arg-Gly-Asp) (Arginine, Glycine, Aspartic acid) having the following general formula (II):



(II)

where:

- R_3 is chosen from benzyl, substituted benzyl, allyl, hydroxypropyl, hydroxyethyl, lower alkyl;
- n is a number chosen from 0, 1, 2;

including the salts, the racemates, the individual enantiomeric forms, the individual diastereoisomeric forms, or their mixtures.

17. The compounds according to Claim 16, characterized in that said lower alkyl is a C_1-C_4 alkyl group.

18. Compound according to Claim 16, characterized in that n is chosen equal to 1 and R_3 is chosen as a benzyl.

19. Compound according to Claim 16, characterized in that n is chosen equal to 2 and R_3 is chosen as a benzyl.

20. The compounds according to Claim 16, characterized in that said R_3 is an allyl.

21. The compounds according to Claim 16, characterized in that said R_3 is hydroxyethyl or hydroxypropyl.

22. The process for the preparation of compounds according to Claim 16, which comprises the following steps:

- reaction of chemoselective deprotection of the carboxylic group of the

compound of the general formula (I) according to Claim 1 and condensation with the dipeptide Arg-Gly appropriately protected and previously prepared;

- reaction of chemoselective protection of the amine group of the azabicycloalkane and subsequent condensation with appropriately protected aspartic acid;
- conversion of glycine by means of transesterification reaction followed by the simultaneous removal of the protective group of glycine and aspartic acid;
- intramolecular cyclization mediated by condensing agents and subsequent deprotection of the protective groups of the side chains of amino acids.

23. The process according to Claim 22, characterized in that said deprotection of the amine group of the azabicycloalkane is obtained by means of catalytic hydrogenation.

24. The process according to Claim 22, characterized in that said conversion of glycine is obtained by transesterification of the methyl ester in benzyl ester and in that said subsequent removal of the protective group of glycine and aspartic acid is obtained by catalytic hydrogenation.

25. Use of the compounds according to Claim 16 as inhibitors of integrines.

26. Use according to Claim 25 for the inhibition of $\alpha v\beta 3$ and $\alpha v\beta 5$ integrines.

27. Use of the compounds according to Claim 16 as drugs for inhibiting angiogenesis.

28. Use of the compounds according to Claim 16 as drugs in the treatment of pathological conditions of a tumoral origin, in metastasized tumoral processes, retinopathies, acute renal damage and osteoporosis.

29. Use of the compounds according to Claim 16 as "reverse-turn" inducers.

30. Use of the compounds according to Claim 16 as mediators for the transport and release of drugs.

31. Pharmaceutical compositions that comprise at least one compound according to Claim 16 in a mixture with vehicles and/or excipients which are

acceptable from the pharmaceutical point of view.

32. Use of the pharmaceutical compositions according to Claim 31 as inhibitors of integrines.

33. Use of the pharmaceutical compositions according to Claim 31 for the inhibition of $\alpha v\beta 3$ and $\alpha v\beta 5$ integrines.

34. Use of the pharmaceutical compositions according to Claim 31 as angiogenesis inhibitors.

35. Use of the pharmaceutical compositions according to Claim 31 in the treatment of pathological conditions of a tumoral origin, in metastasized tumoral processes, retinopathies, acute renal damage and osteoporosis.

36. Use of the pharmaceutical compositions according to Claim 31 as mediators for the transport and release of drugs.